ENVEDA LANDS $311M FOR NATURE-BASED AI DRUG TRIALS

Enveda uses artificial intelligence to identify drug candidates from natural sources, a process the company says reduces development timelines. The company is currently testing treatments for two applications: skin conditions and weight preservation in patients discontinuing GLP-1 drugs. The latter addresses an emerging market need. GLP-1 medications like Ozempic and Wegovy have driven significant weight loss, but patients often regain weight after stopping treatment. Enveda's candidate aims to maintain those gains. The funding round positions Enveda among a growing cohort of biotech startups leveraging AI to streamline drug discovery. The company's nature-derived approach differentiates it from purely synthetic alternatives, potentially offering safety and efficacy advantages. Enveda will use the capital to expand clinical development, advance its pipeline, and scale operations. The startup has not disclosed timelines for trial completion or regulatory submissions.